Answers are grounded in this paper and cite their sources.
Undergoing an era of revolutionary new knowledge and advances in the systemic and surgical treatment of peritoneally disseminated epithelial ovarian cancer (EOC), we never before have been confronted with such a plethora of novel targeted agents, genetically based treatment strategies and cutting edge surgical techniques that enrich our armamentarium in the fight against this deadly disease [1–3]. Still, our art as clinicians is to put all this new body of knowledge into the right context so that we can help our patients without compromising their care through an enthusiastic effort of implementing new therapeutic approaches that are not yet sufficiently validated or confirmed.
No takes yet. Share an insight, caveat, or question.
Fotopoulou et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: